Morepen Begins Commercial Supplies Under Rs 825 Crore Global CDMO Deal

The company said the initial shipment marks the successful transition of the project from the validation and qualification stage to full-scale commercial execution.

Commenting on the development, Sanjay Suri, Managing Director, Morepen Laboratories Limited, said, "This is an important milestone in Morepen's transition toward long-duration global manufacturing partnerships. Our teams have worked closely with the customer through validation, manufacturing readiness and supply-chain planning. Having started execution of commercial supplies, we are focused on scaling up, expanding capacity and building a stronger CDMO platform across additional customer and product opportunities."

Following the first commercial dispatch, the company expects to significantly scale up supplies under the contract during the second quarter of FY2026-27. Subject to customer schedules and regulatory and commercial requirements, Morepen anticipates additional supplies worth around Rs 225 crore in Q2.

To support the growing CDMO business, the company is also expanding its manufacturing infrastructure. Morepen said its total reactor capacity is expected to increase to approximately 600 KL by the end of Q2, with further expansion planned to 800 KL and eventually 1,000 KL in subsequent phases.

The commencement of commercial supplies under the mandate aligns with the company's strategy to build a scalable CDMO platform, deepen long-term customer partnerships, and strengthen its presence in global pharmaceutical manufacturing.

Earlier this month, Morepen Laboratories had announced securing a Rs 825 crore global CDMO mandate, marking one of the company's largest manufacturing contracts.